Merck grants Apeiron rights to develop and commercialize cancer candidate hu14.18-IL2

Merck KGaA

Germany / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Aperion Biologics Inc.

U.S. / Medical Devices and Diagnostics

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced